DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Laryng-O-Jet (Lidocaine Hydrochloride Topical) - Summary

 
 



LARYNG-O-JET SUMMARY

Lidocaine HCl Topical Solution USP, 4% is a sterile, aqueous solution containing a local anesthetic agent and is administered topically.

Lidocaine HCl Topical Solution, 4% is indicated for the production of topical anesthesia of the mucous membranes of the respiratory tract.


See all Laryng-O-Jet indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Laryng-O-Jet (Lidocaine Topical)

Lidocaine/tetracaine peel in topical anesthesia prior to laser-assisted hair removal: Phase-II and Phase-III study results. [2014]
peel"), which air-dries and can be peeled off 30 min post-application... CONCLUSIONS: After a 30-min application, LT peel was effective and well-tolerated

Cervical lidocaine for IUD insertional pain: a randomized controlled trial. [2012]
intracervical 2% lidocaine gel for pain relief with IUD insertion... CONCLUSION: Topical or intracervical 2% lidocaine gel prior to IUD insertion does

Treatment for postoperative wound pain in gynecologic laparoscopic surgery: topical lidocaine patches. [2012]
CONCLUSIONS: Topical lidocaine patches at the laparoscopic port sites reduced

Lidocaine/tetracaine patch (Rapydan) for topical anaesthesia before arterial access: a double-blind, randomized trial. [2012]
non-inferior to subcutaneous local anaesthetic... CONCLUSIONS: Both the lidocaine/tetracaine patch and subcutaneous injection of

Intracervical lidocaine gel for intrauterine device insertion: a randomized controlled trial. [2012]
decreased insertion pain compared to placebo... CONCLUSIONS: Intracervical 2% lidocaine gel does not decrease IUD insertion pain.

more studies >>

Clinical Trials Related to Laryng-O-Jet (Lidocaine Topical)

Tumescent Lidocaine Maximum Safe mg/kg Dosage [Enrolling by invitation]
This pharmacokinetic clinical trial is a dose ranging study of lidocaine in tumescent local anesthesia. The goal is to understand the absorption pharmacokinetic of tumescent lidocaine and to determine an objective (statistical) estimate of the maximum safe mg/kg dosage of lidocaine in tumescent local anesthesia without liposuction.

Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving [Recruiting]
We propose that the systemic administration of lidocaine following the induction of cue-induced craving, relative to saline plus cue-induced craving or lidocaine without cue-induced craving, will block the reconsolidation of cue memories. This will lead to a reduction in cue-induced craving upon repeated testing as well as subsequent cocaine use and basal craving.

Lidocaine: Effect of Lidocaine in Chronic Cough [Completed]
People cough in order to clear their airways. Most coughs are caused by viruses and settle down by themselves, but some people develop persistent coughing which can be anywhere from 8 weeks to several years. This is called chronic cough. People with chronic cough find the symptom distressing and it can have a major impact on their quality of life. Patients with chronic cough often report a sensation at the back of their throat which makes them feel an urge to cough. There is some evidence that Lidocaine (an anaesthetic used during medical procedures) can suppress a person's cough when given to patients via a nebuliser (a machine that turns liquid into a fine mist). It is currently unknown whether using a local anaesthetic, such as Lidocaine, in the form of a throat spray would successfully suppress a person's cough. A throat spray would be an easier treatment option in chronic cough patients. Thus, the investigators research aims to compare cough rates, severity and urge to cough scores between Lidocaine throat spray and nebulised Lidocaine.

Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients [Recruiting]
Prescription drug abuse represents a major healthcare problem, with treatment costs reaching billions of dollars annually in the United States alone. Today opioids are commonly prescribed for chronic non-cancer pain and are only partially effective for short-term pain relief. Whereas opioids are initially part of the solution for pain, it eventually often turns to be a problem in patient with chronic pain. Long-term treatment with opioids can be complicated by development of tolerance, dependency, addiction, abnormal pain sensitivity, hormonal changes, and immune modulation. Unfortunately, the chronic use of anti-inflammatory drugs is associated with a marked increase in adverse effects. The purpose of this study is to determine whether systemic administration of lidocaine provides effective pain relief in opioid dependent chronic pain patients. Investigators intend to demonstrate that lidocaine infusion can improve pain relief and physical function in opioid dependent patients, thus improving compliance and patient satisfaction, which may potentially help wean patients off narcotics. The long-term goal of this proposal is to decrease opioid dependence in chronic pain patients by using lidocaine infusion.

Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization [Recruiting]
Uterine artery embolization (UAE) is a minimally invasive treatment for women with symptomatic fibroids. It is similar to hysterectomy in term of satisfaction and symptoms improvement, with fewer complications and at lower cost. However, the majority of women undergoing UFE experience important pain after the procedure despite optimal analgesia, with one third reporting pain equal or worse than labor. Pain is the more common cause of prolonged hospital stay or readmission. There is need for a simple, efficient way to reduce post-procedural pain. For this prospective randomized study, the hypothesis is that an anesthetic drug, lidocaine, injected in the uterine arteries diminishes pain post-UFE. Patients will be randomized in 3 groups: control, lidocaine injected during embolization, and lidocaine injected after embolization. Pain will be evaluated using a validated scale at 4h and 24h post-intervention. Hospital length-of-stay and total narcotic dose administered will be evaluated in the three groups. This is the first Canadian study evaluating lidocaine use for pain control in UFE patients. Results will be transferable to clinical practice, considering the use of lidocaine is simple and cost is negligible. It could have a great impact on pain management in women undergoing UFE in all practice settings.

more trials >>


Page last updated: 2014-12-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017